All News

SB15 had a comparable safety, pharmacokinetics, and immunogenicity treatment profile to AFL for age-related macular degeneration.

Stormi Gale, PharmD, BCCP, a cardiology pharmacy specialist at Novant Health, discussed the important role of SGLT2 inhibitors in glycemic control.

A single infusion of ciltacabtagene autoleucel produced a lower risk of death and disease progression, as well as deep and durable responses, in heavily pretreated patients with relapsed/refractory multiple myeloma.

Providing this treatment for patients with cancer may be a smoother transition for oncology professionals than they might expect.

Pharmacists should learn the basics of this leading cause of vision loss among adults worldwide.

The ease of administration with new agents for schizophrenia via an injection is advantageous because this patient population is commonly agitated and difficult to administer oral medications to.

Study evaluates the interaction between excessive salt intake and hypertension, cognitive dysfunction, and dementia.

Clinicians are increasingly recognizing the negative impact of the middle-of-the-night dosing required with twice-nightly therapies for narcolepsy.

Brody Maack, PharmD, CTTS, associate professor at the North Dakota State University School of Pharmacy, discussed how telehealth has evolved since its explosion during the COVID-19 pandemic.

The trial will also evaluate the efficacy and safety of a new form of oral pre-exposure prophylaxis for HIV.

Pharmacists who immunize must ensure their knowledge about routine vaccinations for adults and children is up-to-date by reviewing the changes to the immunization schedule each year.

More than ever, patients are turning to OTC products to treat conditions like allergies, arthritis, coughs, colds, migraines, and gastrointestinal issues.

Expert provides numerous resources to learn more about the Centers for Medicare & Medicaid Services Enhancing Oncology Model.

Capivasertib combined with fulvestrant doubled progression-free survival in patients with recurrent or progressed advanced stage HR-positive HER2-negative breast cancer compared to placebo.

Additionally, data from the SCARLET trial presented at ASCO 2023 indicate the safety and efficacy of sotorasib in combination with platinum-based chemotherapy treating non¬–small cell lung cancer.

Alex Mills, PharmD, BCACP, AAHIVP, discussed his presentation at the ASHP 2023 Summer Meeting.

STRONG-HF aimed to study whether rapid-dose escalation of guideline-directed heart failure medications was more beneficial than usual care.

Ambulatory care pharmacy residents play a major role in increasing both patient awareness about recommended vaccination and vaccination rates.

Even with technological advancements, provider involvement and oversight remain essential.

Investigators of the study aimed to determine whether the analytical performance specifications of 24,25(OH)2D could be generated.

Patients can employ numerous measures to alleviate pain, improve mobility, and boost overall health-related quality of life.

As the OTC market has grown, Pharmacy Times has responded by adding new health sections and new OTC products to the survey.

Denise Scarpelli, PharmD, MBA, discussed her presentation at the ASHP 2023 Summer Meeting.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

Systemic treatment options have historically been limited to traditional chemotherapy agents.

Acne, atopic dermatitis, rosacea, urticaria, and sunburn present differently and require specific management.

Clinical trial recruitment in areas such as Alabama have had difficulty with recruiting non-White patients, and at the heart of the problem is a lack of trust.

Golidocitinib (DZD4205) is the first Janus kinase 1 inhibitor to be used for this aggressive and rare form of non-Hodgkin lymphoma.

Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.

Myths, fears, distrust, and misinformation on immunizations can keep patients from benefiting from their protective effects.